MGMT and glioblastoma: In the phase 3 CATNON study of temozolomide and radiotherapy versus radiotherapy alone in newly diagnosed IDH-wild-type glioblastoma, post-hoc analysis revealed patients with MGMT-methylated tumors had superior overall survival compared to MGMT-unmethylated tumors (HR 0.65; 95% CI 0.45–0.92), with a median overall survival of 1.8 years versus 1.4 years, respectively.23 The delay of radiation did not appear to negatively impact the survival of our patient, although a larger sample size is certainly required.